Tremelimumab for Colorectal Cancer

"This clinical trial is not presently enrolling patients. Initially posted on December 7th 2017 and most recently updated January 13th 2022, further research into other trials may be necessary. Of the available studies related to colorectal cancer, there are currently 1090 recruiting participants while 342 of those are investigating Tremelimumab's efficacy."

"Currently, there are 342 trials researching Tremelimumab. Of these, 52 have advanced to Phase 3 clinical trials. The bulk of the studies for this medication can be found in Cordoba, Texas; however, it is also being tested internationally at 13120 sites worldwide."

"Since 2007, AstraZeneca has sponsored research into the potential benefits of Tremelimumab. The initial trial involved 37 people and following its success, Phase 2 approval was granted. Now there are 342 active trials for this medication taking place in 1327 cities across 58 nations."

"At present, this specific medical study is not recruiting participants. According to the clinicaltrials.gov posting dated December 7th 2017 and updated on January 13th 2022, there are currently 1432 other trials in search of volunteers."

"Tremelimumab is a preferred treatment for advanced non-small cell lung cancer and metastatic ureteral carcinoma. It can also be used to treat other ailments such as unresectable stage iii disease or advance directives."

"The main objective of this trial, evaluated over a 30 day period after the last treatment administration, is to measure Grade 1-5 Adverse Events in patients. Secondary outcomes include Response Rate which reflects variations in tumor size and metastasis presence/absence; Overall Progression-Free Survival (PFS) calculated as median survival time without disease progression following intervention; Percentage of Participants With 5 Month PFS determined by evaluating the median survival timeframe free from disease advancement at five months post-treatment; Disease Progression defined by an increase greater than 20% observed between smallest sum on study (including baseline if applicable) and current sum."